Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 7, 2018
OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update
NANTES, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), today reported its consolidated half-year financial results as of June ...
September 7, 2018
Zealand sells royalty streams and milestones for USD 205 million to Royalty Pharma
Copenhagen, September 6, 2018 - Zealand Pharma A/S ("Zealand") (ZEAL.CO), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today ...
September 7, 2018
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation ...
September 7, 2018
Zealand Pharma to attend J.P. Morgan Cazenove and Morgan Stanley Global Healthcare Conferences
Copenhagen, September 7, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the J.P. Morgan Cazenove Pan-European ...
September 7, 2018
Novus Therapeutics to Postpone Offering of Common Stock
IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), ...
September 6, 2018
Kiadis Pharma announces two senior management appointments
Amsterdam, The Netherlands, September 6, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today ...
September 6, 2018
Sensorion Presents Three Posters At The 55th Inner Ear Biology Workshop
MONTPELLIER, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today presented ...
September 6, 2018
Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
September 6, 2018
Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
PASADENA, Calif.--(BUSINESS WIRE)-- Data presented from the lowest two dose cohorts (100mg and 200mg ARO-HBV) Up to 4.0 log10 reduction in HBsAg observed following three ...
September 6, 2018
Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients
REDWOOD CITY, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...
September 6, 2018
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
September 6, 2018
Zosano Pharma to Present Phase 3 Safety Study Update for ADAM™ Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference
FREMONT, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver ...
September 6, 2018
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
WATERTOWN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, ...
September 6, 2018
Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell
AUSTIN, Texas, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, will ring the NASDAQ closing ...
September 4, 2018
BIOPHYTIS Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia
PARIS, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to fight age-related ...
September 4, 2018
Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conference
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, ...
September 4, 2018
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously announced transaction with Juvenescence ...
September 4, 2018
CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA
MONMOUTH JUNCTION, N.J., Sept. 4, 2018 /PRNewswire/ -- CytoSorbents Corporation(CTSO) a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in ...
September 4, 2018
Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
September 4, 2018
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome
REDWOOD CITY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
Page 20 of 117